NCT04539717Completed
FAST (Focused Abbreviated Screening Technique)-MRI Study
Abbreviated MRI for HCC Screening in Cirrhotic Patients (FAST-MRI Study)
Source: ClinicalTrials.gov · Last updated 2 Nov 2026
Brief summary (registry, in English)
The purpose of this study is to compare the diagnostic value of a reconstructed abbreviated Magnetic Resonance Imaging (MRI) from a full clinical exam, compared to ultrasound (US) for screening of liver cancer. Blood markers will be evaluated to determine their correlation to imaging. This study will help to determine whether abbreviated MRI is superior to ultrasound for diagnosis of liver cancer.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 820 (actual)
- First submitted
- 31 Aug 2020
- Start date
- 17 Aug 2020
- Primary completion date
- 31 May 2026
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT04539717
What you commit to
- Study type: Observational
- Participants enrolled: 820
- From 17 Aug 2020 to the primary completion date, 31 May 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior negative screening exam less than 5 months prior to enrollment.
- Prior hepatic resection.
- Post liver transplantation.
- Previously treated HCC or other liver neoplasm.
Other illness
- Patients with chronic renal failure or inability to tolerate contrast.
- Any other condition or factor that in judgment of study investigator may interfere with study completion.
Age
- Age less than 18 years.
Other
- Contra-indications to MRI.
- Inability to undergo MRI due to lack of insurance coverage.
Who the study is looking for
- Liver cirrhosis of any etiology.
- 18 years of age and older.
- Enrolled in screening/surveillance program for HCC.
- Clinically indicated imaging-based screening for HCC.
- Willing and able to complete all study procedures within specified time windows.
- Patient is able to give informed consent for this study.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cedars-Sinai Medical Center Coordinator of this site? Confirm its status | Los Angeles | United States | Unknown status |
| Icahn School of Medicine at Mount Sinai Coordinator of this site? Confirm its status | New York | United States | Unknown status |
Related publications
- Quality of Gadoxetate-enhanced MRI versus US during Hepatocellular Carcinoma Screening in Participants with Cirrhosis.Radiology · 2026 · PMID 41665498
This page is information, not medical advice. Discuss any trial with your doctor.